Patents Assigned to Shanxi Zhendong Pilot Biological Science And Technology Co., Ltd.
  • Patent number: 9303006
    Abstract: Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the line leaf inula flower lactone A shows positive therapeutic effect on EAM. Line leaf inula flower lactone A is used as the sole active ingredient and combined with a conventional pharmaceutical carrier in a drug for treating myocarditis, and the pharmaceutical composition may be in the form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 5, 2016
    Assignee: SHANXI ZHENDONG PILOT BIOLOGICAL SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Weidong Zhang, Lei Shan, Huizi Jin, Juan Su, Huiliang Li, Yunheng Shen, Xike Xu, Runhui Liu
  • Patent number: 9278948
    Abstract: Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 8, 2016
    Assignee: Shanxi Zhendong Pilot Biological Science And Technology Co., Ltd.
    Inventors: Weidong Zhang, Lei Shan, Juan Su, Huizi Jin, Huiliang Li, Yunheng Shen, Xike Xu, Runhui Liu